Bernstein raises Molina Healthcare stock price target on medical costs

Molina Healthcare posted Q1 2026 adjusted EPS of $2.35, above consensus at $1.95, but revenue was mixed with premium revenues of $10.17 billion missing estimates by 1.2% and total revenue of about $10.80 billion missing by 0.7%. The company reaffirmed 2026 adjusted EPS guidance of at least $5.00 and premium revenue of roughly $42 billion, but lowered GAAP EPS guidance to at least $1.90 from more than $3.20. Bernstein SocGen raised its price target to $208 from $173, while other analysts also lifted targets, reflecting cautious optimism despite a higher medical loss ratio of 91.1%.

Analysis

MOH’s reset is less about one strong quarter and more about the market finally pricing in that the earnings power base is stabilizing after a period of benefit-cost normalization. The meaningful signal is that management is holding full-year adjusted guidance while the low-end GAAP guide gets cut sharply; that usually tells you the core franchise is intact, but reserve/revenue timing and accounting noise still matter. For investors, the setup is a classic quality-value tension: the stock can rerate if medical cost trends stay benign into the next bid cycle, but any wobble in exchange membership or utilization will hit the multiple immediately because expectations are now elevated.

The second-order winner is not just MOH shareholders; it is any managed-care peer with similar exposure to exchange and Medicaid margins if the market starts extrapolating a friendlier 2026 cost curve across the group. The loser is the short book in lower-quality health insurers, because one or two more quarters of stable medical loss ratios would force factor rotation into names with visible earnings revisions. That said, the recent analyst target resets suggest the Street is moving to a higher 2027 earnings base, which reduces near-term upside from pure multiple expansion unless estimates keep rising.

The main risk is that this is a “good quarter, bad setup” story: the stock has already re-rated quickly, so any slight miss in premium growth or any medical cost acceleration over the next 1-2 reporting cycles could compress the multiple back faster than fundamentals deteriorate. The contrarian view is that the market is still underestimating how much of the upside is already in the revised earnings path; if 2026 EPS only lands at the low end of guidance, current valuation can look less cheap than screen-based fair value models imply. In other words, MOH is more of a medium-term estimate revision trade than a clean long-term compounder at this price.

Key Decisions for Investors

• Trim tactical longs in MOH into strength over the next 1-2 weeks; keep only a residual position for 2H26 estimate revisions. Risk/reward has shifted from asymmetric upside to more balanced execution risk.
• For new money, use MOH only on a 5-8% pullback or after confirmation of another quarter of sub-consensus medical cost trend; otherwise the entry point leaves too little margin for error.
• Pair trade: long MOH / short a weaker-capitalized managed-care peer basket over 1-3 months if the goal is relative-value exposure to improved cost trends. The thesis is estimate revisions, not sector beta.
• Buy MOH downside protection rather than outright shorting: use 3-6 month puts or put spreads to hedge against one bad utilization print, since the stock has already had a sharp weekly move and can gap on small guidance changes.
• Watch for analyst estimate revisions over the next 30-45 days; if the upward EPS revision trend broadens beyond the current few targets, add to the long. If revisions stall, assume the rerating is mostly done.